Events

PLacental expanded (PLX) cells are placenta-derived, mesenchymal-like adherent stromal cells expanded using a bioreactor system which provides a three dimensional (3D) micro-environment enabling tightly controlled expansion. Accumulated data from multiple in vitro and in vivo experiments indicate that these cells act via a paracrine or endocrine manner to facilitate healing of damaged tissue. Pluristem’s two lead placenta-derived cell products, PLX-PAD and PLX-R18, are each in clinical development for several indications. PLX-Immune is in non-clinical development stages for Cancer. Data from non-clinical as well as clinical studies will be presented.

The current talk will present evidences that each cancer has its own unique volatile molecular print and, therefore, the presence of one cancer would not screen out others. Based on this concept, a new generation of biomedical devices for achieving personalized diagnosis of various cancers in a noninvasive, inexpensive and portable manner via various body fluids (e.g., breath or skin) will be presented and discussed.